Recent quarterly results show Cryoport reporting losses but with revenues exceeding prior periods. The company continues to expand its service offerings and global reach through strategic partnerships and supports a growing number of clinical trials globally.

• Cryoport reported a net loss for Q2 2026 but revenue exceeded prior periods, indicating ongoing demand for its solutions [N1].
• The company reported a Q1 2026 loss with revenue above expectations, reflecting continued operational challenges alongside revenue growth [N4].
• Craig-Hallum initiated coverage of Cryoport with a buy recommendation in March 2026, highlighting market interest [N8].
• Cryoport's Q1 2026 earnings transcript provides detailed insights into operational performance and strategic initiatives [N3].

Cryoport benefits from growth in the cell and gene therapy market, with increasing demand for specialized temperature-controlled logistics and storage solutions. Expansion of its Life Sciences Services segment, including BioLogistics and BioStorage/BioServices, and steady growth in Life Sciences Products revenue demonstrate market acceptance. The company's global presence and strategic partnerships enhance its ability to serve international customers. Strong liquidity provides financial flexibility to invest in growth initiatives and geographic expansion. Continued innovation and broadening of service offerings could support sustained revenue growth.

Cryoport faces risks from its dependence on third-party manufacturers for critical components, which could cause supply delays or increased costs. The company operates in a competitive and rapidly evolving market where technological obsolescence or superior competitor offerings could erode market share. Product liability risks, especially given the use of products in sensitive medical applications, could lead to costly litigation or reputational damage. International operations expose the company to currency fluctuations, geopolitical risks, and regulatory challenges. Additionally, the company has a history of losses and an accumulated deficit, indicating ongoing profitability challenges.

Cryoport's moat is anchored in its specialized, integrated temperature-controlled supply chain solutions tailored for the life sciences sector, especially the rapidly growing cell and gene therapy market. Its global footprint with facilities and operations across key regions, combined with a broad service and product portfolio, creates barriers to entry. The company's established relationships with biopharma and pharmaceutical customers, support for numerous clinical trials including advanced phase 3 trials, and strategic partnerships such as with DHL, further strengthen its competitive position. The complexity and regulatory requirements of handling sensitive biological materials also contribute to its defensibility.

• International Operations Risks: Exposure to currency fluctuations, political instability, tariffs, and regulatory changes in multiple countries could adversely affect sales, profitability, and cash flows [S1].
• Supply Chain Dependencies: Reliance on third-party manufacturers for components, some sole sourced, creates risk of delays, increased costs, or inability to meet customer demand [S1].
• Product Liability and Quality Risks: Potential errors or defects in products, especially in human reproductive medicine applications, could lead to reputational harm, litigation, increased costs, and product recalls [S1].
• Public Health Crises Impact: Pandemics or epidemics could disrupt manufacturing, supply chains, workforce availability, and financial performance [S1].
• Profitability and Financial Condition: Despite recent net income, the company has a significant accumulated deficit and may continue to incur losses, impacting financial stability [S1].

• Cryoport, Inc. is a global provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on the cell and gene therapy (CGT) market [S1].
• The company operates two reportable segments: Life Sciences Services (including BioLogistics and BioStorage/BioServices) and Life Sciences Products [S1].
• Life Sciences Services revenue was $96.5 million for the year ended December 31, 2025, up 17.6% year-over-year, driven by BioLogistics Solutions and BioStorage/BioServices growth [S1].
• Life Sciences Products revenue was $79.7 million for the year ended December 31, 2025, up 6.6% year-over-year [S1].
• Total revenue for the year ended December 31, 2025 was $176.2 million, a 12.4% increase from 2024 [S1].
• The company supports a broad range of customers including biopharmaceutical, pharmaceutical, animal health, reproductive medicine, academic institutions, research, and government agencies [S1].
• Cryoport has a global footprint with operations in the Americas, EMEA, and APAC regions, including the US, UK, France, Netherlands, Belgium, Germany, Japan, and China [S1].
• The company divested its CRYOPDP business, classifying it as discontinued operations, and entered a strategic partnership with DHL to enhance its business in EMEA and APAC [S22].
• As of June 30, 2026, Cryoport had cash and cash equivalents of $269.3 million and short-term investments of $127.4 million, with a current ratio of 2.08 and a cash ratio of 1.79, indicating strong liquidity [S2].
• For the quarter ended June 30, 2026, revenue was $48.97 million with a net loss of $8.26 million and basic and diluted EPS of -$0.20 [S2].
• The company has historically incurred significant losses but reported net income of $78.3 million for the year ended December 31, 2025, with an accumulated deficit of $688.9 million as of that date [S1, S7].
• Cryoport faces risks related to international operations including currency fluctuations, political and economic instability, tariffs, and regulatory changes [S1].
• Supply chain risks include dependence on third-party manufacturers for components, with potential delays or increased costs impacting operations and customer satisfaction [S1].
• Product risks include potential errors or defects, especially given the use of products in human reproductive medicine, which could lead to reputational damage, litigation, and increased costs [S1].
• The company maintains product liability insurance but coverage may not be adequate for all claims, and uninsured claims could materially affect financial condition [S1].
• Cryoport's business operations could be materially affected by pandemics or public health crises, impacting supply chains, workforce, and financial performance [S1].
• The company is expanding sales, marketing, and distribution capabilities globally, which involves costs and execution risks [S1].
• Cryoport's revenue is geographically diversified with approximately $131.3 million from the Americas, $25.1 million from EMEA, and $19.8 million from APAC for the year ended December 31, 2025 [S21].
• The company supports a growing number of clinical trials globally, including 760 clinical trials at year-end 2025, with 86 in phase 3, indicating engagement in advanced stages of cell and gene therapy development [S1].
• Recent news reports indicate Cryoport reported Q2 2026 loss but revenue exceeded expectations, and Q1 2026 loss with revenue above estimates [N1, N4].
• Craig-Hallum initiated coverage of Cryoport with a buy recommendation in March 2026 [N8].